secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001654954-21-012080
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q3 net loss $6.3M; revenue minimal from TRUFORMA launch; cash $271.4M
------------------------------------------------------------------------------

- Net loss of $6.3M ($0.01/share) vs $5.0M loss in Q3 2020; nine-month loss $15.1M.
- Revenue from TRUFORMA products was $22,514; commercial launch began March 2021.
- Cash and equivalents $271.4M at Sept 30, 2021; pro forma after PulseVet acquisition ~$199.5M.
- SG&A expense rose 166% to $6.1M, driven by share-based compensation and PulseVet deal costs.
- R&D expense fell 89% to $0.3M as initial TRUFORMA assays completed; development shifts to commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495421012080/0001654954-21-012080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495421012080/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-21-012080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer